A non-linear association between blood tumor mutation burden and prognosis in NSCLC patients receiving atezolizumab.

ABSTRACT: A significant association between high blood-based tumor mutational burden (bTMB) and improved progression-free survival (PFS) was observed in advanced non-small cell lung cancer (NSCLC) receiving atezolizumab. However, this result was unrepeatable in a recent prospective study. We hypothesized that there might be a non-linear association between bTMB and survival. This study used the clinical and genetic data from POPLAR (n = 105, training set) and OAK (n = 324, validation set) trials. The non-linear association between bTMB and survival was assessed using restricted cubic spline (RCS). The cutoff values for bTMB were calculated via X-tile software. Non-linear relationships were observed between bTMB and PFS and overall survival (OS) in RCS plots (both P _{non-linearity} <

SUBMITTER: Nie W 

PROVIDER: S-EPMC7051187 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature